Skip to main content
CLDX
NASDAQ Life Sciences

Celldex的巴索利单抗（Barzolvolimab）在2期荨麻疹研究中显示出深远、持久的生活质量改善

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$30.84
Mkt Cap
$2.053B
52W Low
$14.4
52W High
$34.52
Market data snapshot near publication time

summarizeSummary

Celldex Therapeutics在AAD 2026上展示了其研究性药物巴索利单抗（barzolvolimab）在慢性自发性荨麻疹（CSU）、冷性荨麻疹（ColdU）和症状性皮肤图形症（SD）中的2期数据，数据显示出患者生活质量（QoL）在所有测量领域的快速、深远和持久的改善，94%的控制良好的CSU患者在第52周达到DLQI 0/1。关键的是，分析表明了持续的停药后生活质量改善，并表明了潜在的疾病修饰，强化了巴索利单抗作为一流治疗的特征。这强有力的生活质量数据显著降低了正在进行的CSU和CIU的3期试验风险，如公司之前在10-K中所述，并通过展示超出症状控制的明确患者益处来增强该药物的商业潜力。投资者将关注来自正在进行的3期试验的进一步更新。

在该公告发布时，CLDX的交易价格为$30.84，交易所为NASDAQ，所属行业为Life Sciences，市值约为$20.5亿。 52周交易区间为$14.40至$34.52。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CLDX - Latest Insights

CLDX
Apr 29, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Celldex Seeks Shareholder Approval for 3.4M Share Increase in Equity Incentive Plan
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 06, 2026, 10:53 AM EDT
Source: GlobeNewswire
Importance Score:
7
Celldex Therapeutics Secures $345M from Public Offering, Underwriters Fully Exercise Option
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 5:14 PM EDT
Filing Type: 424B5
Importance Score:
8
Celldex Therapeutics Prices $300M Public Offering to Fund Barzolvolimab Commercialization and Pipeline
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Celldex Therapeutics Prices $300 Million Public Offering, Significant Dilution Expected
Sentiment: Negative
View Wiseek Article
CLDX
Apr 01, 2026, 9:48 PM EDT
Source: Reuters
Importance Score:
8
$300 Million Stock Offering Priced by Celldex at $29.00 Per Share
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 01, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex Proposes Public Stock Offering to Fund Barzolvolimab Commercialization
Sentiment: Negative
View Wiseek Article
CLDX
Mar 27, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex's Barzolvolimab Shows Profound, Durable Quality of Life Improvements in Phase 2 Urticaria Studies
Sentiment: Positive
View Wiseek Article
CLDX
Mar 01, 2026, 9:45 AM EST
Source: GlobeNewswire
Importance Score:
8
Barzolvolimab Retreatment Shows Profound Efficacy in Cold Urticaria and SD, Reinforcing Best-in-Class Profile
Sentiment: Positive
View Wiseek Article
CLDX
Feb 27, 2026, 2:45 PM EST
Source: GlobeNewswire
Importance Score:
9
Barzolvolimab Shows Sustained Efficacy, Disease Modification in Phase 2 Urticaria Data
Sentiment: Positive
View Wiseek Article
CLDX
Feb 25, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
Celldex Therapeutics Advances Multiple Clinical Programs, Secures Liquidity Through 2027
Sentiment: Positive
View Wiseek Article